Improved effect of glibenclamide on administration before breakfast

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Glibenclamide is a sulfonylurea drug used to manage Type 2 diabetes.
• Optimizing glibenclamide administration timing may enhance its therapeutic efficacy.
• Understanding the impact of meal timing on drug absorption and glucose control is crucial.

Purpose of the Study:

• To investigate whether administering glibenclamide before meals improves its therapeutic effect in Type 2 diabetes.
• To compare the efficacy of glibenclamide given before meals versus with meals.
• To compare different glibenclamide dosing strategies (2.5 mg t.i.d. vs. 7.5 mg single morning dose).

Main Methods:

• A study involving six treatment-naive Type 2 diabetic patients.
• Comparison of glibenclamide 2.5 mg administered before meals, with meals, and a single 7.5 mg morning dose.
• Measurement of plasma insulin (IRI) and blood glucose levels after standardized meals.

Main Results:

• Glibenclamide administration, regardless of timing, increased plasma IRI and reduced blood glucose compared to no drug.
• No significant differences in IRI response were observed across different administration timings.
• A significantly greater reduction in post-breakfast blood glucose occurred when 2.5 mg glibenclamide was taken before the meal.

Conclusions:

• Administering glibenclamide 2.5 mg before breakfast may enhance glucose utilization post-meal.
• Earlier attainment of effective glibenclamide concentrations appears to improve glycemic control.
• Meal timing influences the effectiveness of glibenclamide in Type 2 diabetes management.